Benjamin Rogers, MD
Internal Medicine · Cullman, ALNPI 1801023502
Payments from drug & device makers
Across 232 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$680
- Novo Nordisk$652
- AbbVie$430
- Johnson & Johnson$232
- Astellas Pharma US Inc$217
- AstraZeneca$207
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,708100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $680 |
| Novo Nordisk | 42 | $652 |
| AbbVie(2 entities) | 23 | $430 |
| Johnson & Johnson | 16 | $232 |
| Astellas Pharma US Inc | 13 | $217 |
| AstraZeneca | 7 | $207 |
| Amgen(2 entities) | 10 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $122 |
| E.r. Squibb & Sons, L.L.C. | 7 | $90 |
| GSK | 5 | $72 |
| Novartis | 4 | $69 |
| Boehringer Ingelheim | 5 | $68 |
| Medicomp Inc | 1 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Eagle Pharmaceuticals, Inc. | 1 | $64 |
| Bayer | 4 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Ironwood Pharmaceuticals, Inc | 3 | $45 |
| Biogen | 2 | $44 |
| Radius Health, Inc. | 2 | $35 |
| CSL Behring | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| Merck | 2 | $27 |
| Medtronic | 1 | $25 |
| Braintree Laboratories, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| Seqirus USA Inc | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$115
How this compares
$3,708 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 190 | $150,080 |
| OzempicSemaglutide | 124 | $137,759 |
| TrulicityDulaglutide | 100 | $108,864 |
| FarxigaDapagliflozin Propanediol | 116 | $78,815 |
| MounjaroTirzepatide | 71 | $77,339 |
| JardianceEmpagliflozin | 79 | $71,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $64,084 |
| XareltoRivaroxaban | 52 | $47,199 |
| RybelsusSemaglutide | 27 | $38,204 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $32,559 |
| Repatha SureclickEvolocumab | 31 | $28,874 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $24,862 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $21,936 |
| MyrbetriqMirabegron | 43 | $21,905 |
| InvokanaCanagliflozin | 28 | $20,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $652 | $175,964151 claims |
| PfizerEliquis | $680 | $150,080190 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $72 | $96,098131 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $207 | $94,362146 claims |
| Boehringer IngelheimJardiance, Glyxambi | $68 | $81,16991 claims |
| Johnson & JohnsonXarelto, Invokana | $232 | $67,84580 claims |
| Astellas Pharma US IncMyrbetriq | $217 | $21,90543 claims |
| MerckJanuvia | $27 | $19,94227 claims |
| AbbVieLinzess | $430 | $9,68114 claims |
| Braintree Laboratories, Inc.Sutab | $22 | $3,71223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Cullman
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.